Adeno-associated viral (AAV) vectors have been broadly used for gene transfer in vivo for various applications. However, AAV precludes the use of most of the original large-sized tissue-specific promoters for expression of transgenes. Efforts are made to develop highly compact, active and yet tissue-specific promoters for use in AAV vectors. In this study, we further abbreviated the muscle creatine kinase (MCK) promoter by ligating a double or triple tandem of MCK enhancer (206-bp) to its 87-bp basal promoter, generating the dMCK (509-bp) and tMCK (720-bp) promoters. The dMCK promoter is shorter but stronger than some previously developed MCK-based promoters such as the enh358MCK (584-bp) and CK6 (589-bp) in vitro in C2C12 myotubes and in vivo in skeletal muscles. The tMCK promoter is the strongest that we tested here, more active than the promiscuous cytomegalovirus (CMV) promoter. Furthermore, both the dMCK and tMCK promoters are essentially inactive in nonmuscle cell lines as well as in the mouse liver (4200-fold weaker than the CMV promoter).
Instruction
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder and is the most common muscle-wasting disease in humans, affecting one in three thousand males.
1,2 DMD presents its traumatic and painful physical symptoms early in a child's life. Also, as there are no effective treatments available, 3, 4 DMD patients eventually become wheel-chair bound in their early twenties due to progressive muscle weakness, with death resulting from respiratory or cardiac failure. 5 As the genetics of this disease have been well characterized, gene therapy offers hope for treatment. 3 For muscular dystrophies and other muscle degenerative disorders, the use of muscle-specific promoters is highly desirable in the development of gene therapy vectors. Nonspecific promoters can potentially elicit immune responses against the delivered gene and/or gene vector. A main concern in the development of DMD gene therapy vectors is that widespread targeted gene expression in tissues such as the liver and lung will result in overall toxicity and/or the initiation of a host immune response against tissues expressing the transgene or gene vector. [6] [7] [8] The viral promoters, such as human cytomegalovirus (CMV) immediate-early gene promoter, achieve high levels of nonspecific gene expression; in contrast, the use of the muscle creatine kinase (MCK) promoter is specific to muscle tissue and can avoid the potentially harmful effects of ectopic transgene expression. [9] [10] [11] [12] However, the MCK promoter is less active than viral promoters, and its large size (6.5 kb) makes it incompatible with adeno-associated viral (AAV) vectors, a noteworthy gene delivery vehicle with a 4.5-kb capacity for the treatment of muscular dystrophies and other degenerative disorders. [13] [14] [15] We have shown previously that a truncated MCK promoter (enh358MCK, 584-bp) could achieve musclespecific expression of the human minidystrophin genes (3.8-4.2 kb) in dystrophin-deficient mdx mice, ameliorate pathologies and improve muscle contractile function in mdx mice. 15, 16 However, the expression activity was less than the CMV promoter seen consistently in studies from other investigators. 8, 13 Recently, the MCK enhancer has been used to build a hybrid SV40 promoter for muscletargeted long-term transgene expression. 17 The MCK enhancer inserted in retrovirus long terminal repeat (LTR) also led to stable and specific expression of human factor IX in skeletal muscle. 18 Transgenic and tissue culture analyses showed that the MCK promoter was expressed at a high level only in differentiated skeletal and cardiac muscles. 19, [20] [21] [22] [23] However, most comprehensive work has been done by Hauschka's laboratory on the modification and optimization of MCK-based muscle-specific promoters. 9, [24] [25] [26] [27] We have made our own efforts to further reduce the size and retain/improve the strength and specificity of the truncated MCK promoters, as the minidystrophin genes we tested for gene therapy have the coding sequences around 4.0 kb, whereas the AAV vectors could only afford less than 4.7 kb of foreign gene cassette. This has left little room to accommodate the promoter and polyA sequences in addition to the minidystrophin gene. To further shorten the MCK promoters, we have ligated a modified MCK enhancer sequence (2R5S) created by Hauser et al. 25 to a highly truncated miniature MCK basal promoter (position À80 to +7), generating new MCK promoters containing double or triple enhancers. Our results indicate that expression levels of the modified dMCK or tMCK promoter combined with two or three 2RS5 enhancer sequences were significantly higher than a few earlier versions of truncated MCK promoters. This expression was tissue specific and the expression correlated primarily with fast-twitch muscles, which would benefit the therapeutic treatment of muscular dystrophies and other muscle degenerative disorders as well as injuries.
Results
The dMCK and tMCK promoters are highly active in differentiated myotubes but not in other cell types in vitro
As depicted in Figure 1a , four different MCK promoters with the luciferase gene were constructed in AAV vectors, whereas the CMV promoter served as the control in this study. The C2C12 cell line, a murine myoblast cell line, was used to evaluate the levels of luciferase expression by transfection. Differentiation of C2C12 myoblast cells to myotubes was confirmed by the morphology changes at 3-4 days after they were plated in low-serum differentiation medium ( Figure 2A ). The cells were harvested on days 1, 2, 3 and 4 posttransfection and differentiation, and luciferase expression was measured. As shown in Figure 2B , the expression from the nonspecific CMV promoter control Modified MCK promoter Ebox: -1256 to -1050 Figure 1 AAV-Luc vectors and C2C12 myoblasts differentiation. Schematic illustration of five AAV vectors containing the luciferase gene were constructed as described previously (see Materials and methods). Both AAV-enh358MCK-Luc and AAV-CK6-Luc vectors contain the MCK regulation region truncated to base pairs À358 to +7, but the latter has a single modified 2R5S enhancer sequence (206-bp). Both AAVdMCK-Luc and AAV-tMCK-Luc vectors contain the highly truncated regulation region down to 87 base pairs (À80 to +7); however, the former has a double tandem of 2R5S enhancer sequences and the latter has a triple tandem of 2R5S enhancer sequences. The AAV-CMV-Luc vector serves as a control. Note that the abbreviated Luc and E represent luciferase gene and the MCK enhancer, respectively.
The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al vector was very high at day 1, but gradually decreased over the next 3 days. For all four MCK-derived promoters, however, there was a general trend of very lower levels of activities on day 1 and much higher levels of activities on days 3 and 4, along with C2C12 cell differentiation. For example, on day 1 post-transfection, the dMCK and tMCK promoters had very low levels of activities, approximately 100-fold lower than the CMV promoter. However, after myoblasts differentiation to myotubes, the dMCK and tMCK promoters had their activities 3-fold and 14-fold higher, respectively, than the CMV promoter on day 4 post-transfection. In addition, on day 4, the dMCK promoter had activities 13-fold and 5-fold higher than the enh358MCK and the CK6 The CMV promoter drove very high levels of expression compared to the MCK promoters on day 1, and then gradually decreased over the next 2 days. After C2C12 cell differentiation at days 3 and 4, significantly higher levels of activities were observed for the CK6 promoter compared with the enh358MCK promoter (Po0.005), whereas the dMCK and tMCK promoters had higher levels of activities than both the enh358MCK and the CK6 promoters (Po0.005). The dMCK promoter showed similar activity as the CMV promoter (P40.05) at day 3, but higher level of activity at day 4. Furthermore, the tMCK promoter activity was higher than the CMV promoter at days 3 and 4 (Po0.05). (C) The CMV promoter demonstrated very high levels of activity in 293 cells; in contrast, all three modified MCK promoters (CK6, dMCK and tMCK) demonstrate similar levels of activities. All the MCK promoters showed significantly lower level of gene expression in 293 cells when compared to the CMV promoter (*Po0.005).
The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al promoters, respectively, whereas the tMCK promoter had activities 58-fold and 23-fold higher than the enh358MCK and the CK6 promoters, respectively. We have also tested the above promoters in human 293 cells, a nonmuscle cell line (human embryonic kidney cell). As expected, the CMV promoter had very high levels of expression at 24 h post-transfection. In contrast, all three modified MCK promoters (CK6, dMCK and tMCK) had similarly low levels of luciferase expression, 227-to 818-fold lower than the CMV promoter. The enh358MCK promoter displayed 180-fold lower level of activity than the CMV promoter ( Figure 2C) . The above-mentioned data demonstrated that the dMCK and tMCK promoters achieved superior levels of in vitro luciferase expression in the terminally differentiated myotubes, but not in the undifferentiated myoblast cells and nonmuscle 293 cells.
The dMCK and tMCK promoters in AAV vectors show high efficiency and specificity in muscles but not in liver in vivo
To further characterize these promoters, we performed in vivo experiments in 2-month-old C57/BL10 mice by i.m. injection of AAV luciferase vectors driven by different promoters. One month after the i.m. injection, the tMCK promoter yielded the highest levels of activity 1 month post-treatment, fourfold greater than the CMV, dMCK and CK6 promoters ( Figure 3a ). More specifically, the CK6, dMCK and tMCK promoters showed significantly higher levels of activities than the original enh358MCK vector. The in vivo results are consistent with the in vitro observations and further demonstrate the ability of the dMCK and tMCK promoters to approach and even surpass the activity of the CMV promoter.
We then performed AAV vector liver delivery in adult C57/BL10 mice by intrasplenic infusion, which is an easy and less-invasive alternative route to achieve portal vein delivery and has been used by many labs including our own. At 15 days post-treatment, the CMV promoter group demonstrated the highest levels of expression in the liver compared to all four MCK promoter groups, which showed at least 200-fold lower levels of activities than the CMV promoter ( Figure 3b ). On average, the dMCK and tMCK promoters had the trend of lower levels of activities than the enh358MCK and CK6 promoters in the liver.
Examination of the dMCK promoter in transgenic mice with LacZ gene and a minidystrophin gene
To directly evaluate the activity and tissue specificity of our dMCK construct in vivo, we generated transgenic mice. The endogenous expression of the LacZ gene in these transgenic mice avoided interference factors, such as an immune response to the AAV viral vector in C57/ BL10 28 and mdx mice. 7 The 10-day-old dMCK-LacZ transgenic mice were strongly positive for b-galactosidase expression in all the posterior skeletal muscles, while the negative control littermates were clearly negative for X-gal staining (Figure 4a ). High levels of b-galactosidase were also observed in the skeletal muscles of the forelimbs and the face of dMCK-LacZ transgenic mice (Figure 4b ), but not in the negative control littermates (Figure 4c ). We found the skeletal muscles of the hind limbs and intercostal muscles in the dMCK-LacZ transgenic mice to be strongly positive for b-galactosidase (Figure 4d and e). The diaphragm was also observed to have weak LacZ expression (Figures 4f). Upon examining the dMCK-LacZ founder mice, b-galactosidase activity was not observed in the brain, heart or liver (data not shown). Taken together, these data indicate that the dMCK promoter achieved strong, widespread and muscle-specific LacZ expression in vivo.
We continued our transgenic mice studies by evaluating the activity of the dMCK promoter in mdx mice to see how the promoter performed in this small animal model commonly used for DMD gene therapy studies. Both the 20-day-old dMCK-LacZ transgenic C57/BL10 and mdx mice showed strong expression of the LacZ gene. The expression was observed throughout the muscles of the hind limbs shown by transverse section (Figure 4g and h), indicating that the LacZ expression was not restricted to the muscle surface. The hind limb muscle of the C57/BL10 negative control littermate was negative for LacZ expression (Figure 4i ).
The dMCK promoter shows overt preferences to fast-twitch myofibers over slow twitch Figure 3 Comparison of the activities and specificities of the MCK promoters in muscle and liver tissues. (a) The tMCK promoter was observed to have the highest level of activity; it was higher than the CMV and other MCK-derived promoters ( & Po0.005). Both the dMCK and CK6 promoters showed similar activities as the CMV promoter, but they are higher than the enh358MCK promoter (*Po0.005). (b) The CMV promoter demonstrated the highest activity in the liver when compared with the enh358MCK, the CK6, the dMCK and the tMCK promoters (*Po0.005). There was no difference between the activities of four MCK promoters in the liver.
The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al were killed at the age of 6 months to identify longterm minidystrophin gene expression. We found highly efficient expression of the minidystrophin gene in the skeletal muscles of gastrocnemius, tibialis anterior, quadriceps as well as intercostal muscles (Figure 5a-d) , but not in the diaphragm and heart (Figure 5e and f), consistent with the observation in the dMCK-LacZ transgenic mice.
To identify the preference of the dMCK promoter in different myofiber types, we analyzed the gastrocnemius (GAS) of minidystrophin transgenic mice at the age of 6 months by immunofluorescent (IF) staining. As shown in Figure 6 , the C57/BL10 positive control tissue displayed even and strong dystrophin expression (panels a and c) and was comprised primarily of fast-twitch fibers (panel b) and less slow-twitch fibers (panel d, asterisks). We found that every fast-or slow-twitch fiber was positive for dystrophin gene expression. The mdxnegative control tissue was negative for dystrophin expression, with only a few sporadic revertant dystrophin-positive myofibers (panels e and g). Also, the majority of myofibers in mdx GAS were observed to be fast twitch (panel f) with fewer slow-twitch fibers (panel h, asterisks). The GAS muscles of the transgenic mdx mice showed strong uniformed expression of minidystrophin, as well as peripherally localized nuclei (panels i and k). Moreover, myofiber morphology was visually identical to the wild-type tissue. The majority of myofibers in transgenic mdx mice were observed to be fast twitch (panel j) and also positive for minidystrophin expression (panel i). Only a few slow-twitch myofibers were identified, and they were all negative for minidystrophin expression (panel l, asterisks). These results suggest that the dMCK promoter displays an overt preference in fast-twitch myofibers over slow myofibers.
Synthetic promoter C5-12 is active in muscle and heart without myofiber-type preference Previously, we have used the synthetic C5-12 (Syn) promoter [29] [30] [31] [32] for systemic gene delivery in hamsters. 33 This promoter was active in both heart and skeletal muscles, including the diaphragm, throughout the body. However, we did not investigate if it also displays myofiber-type preference. Here, we used the Syn promoter to drive the human minidystrophin genes 15 and packaged the vectors in AAV1, AAV6 and AAV9 vectors. As shown in Figure 7a , systemic delivery of the AAV9 vector The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al Figure 5 Dystrophin expression in dMCK-human minidystrophin transgenic mice. The muscle tissues of the transgenic mice, aged 6 months, were collected for dystrophin IF staining (in red). Nuclei were stained by 4,6-diamidino-2-phenylindole (in blue). The results showed that the dMCK promoter has high activity in the fast skeletal muscles such as GAS (a), TA (b), QUAD (c) and ITM (d), but is absent in slow muscles such as DIA (e) and heart (f). All panels are shown at Â 100 original magnification. Figure 6 Evaluation of dystrophin expression in fast and slow twitch myofibers. GAS muscles were isolated from 6-month-old C57/BL10, mdx and dMCK-human minidystrophin transgenic mice (Tg mdx). Tissue sections were consecutively stained for dystrophin expression. The first two columns from the left side represent tissues stained for dystrophin (panels a, e and i: green IF) and fast myosin fibers (panels b, f and j: red IF); the next two columns represent tissues stained for dystrophin (panels c, g and k: green IF) and slow myosin fibers (panels d, h and l: red IF). Nuclei were stained by 4,6-diamidino-2-phenylindole (in blue). The asterisks shown within each mouse group (rows) indicate the same slow-twitch myofiber. All panels are shown at Â 400 original magnification.
The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al containing the syn-minidystrophin (Dys D 4173) cassette achieved high expression of the minidystrophin gene in the heart of mdx mice, much higher than the AAV6 vector, confirming the Syn promoter activity in the cardiac muscles. Next, we examined the fiber-type preference of the Syn promoter in the skeletal muscles. As shown in Figure 7b , both fast-and slow-twitch myofibers had minidystrophin (Dys D 3990) expression driven by the Syn promoter. This promoter did not have any discernable preference over the myofiber types compared with the enh358MCK and dMCK promoters. Finally, we examined if the addition of the 2R5S enhancer used in early experiments could also enhance the Syn promoter activity. The Syn promoter with or without the 2R5S enhancer sequence was used for minidystrophin gene expression. We found that the addition of the MCK enhancer indeed enhanced the activity of the Syn promoter by two-to threefold, as shown by IF staining (Figure 7c , upper panels) and western blotting (Figure 7c , lower panel). The compact skeletal muscle-specific promoters for AAV-based gene therapy B Wang et al
Discussion
In our previous studies, we used a truncated penh358MCK promoter 9 to drive the human minidystrophin genes in the AAV vectors. Those results showed muscle-specific expression and functional recovery of dystrophic skeletal muscle, but the expression was lower than that of the CMV promoter. 8, 9, 21, 26, 34, 35 In spite of these successes, we are still seeking to optimize small promoters for the use in AAV vectors in muscle tissues for different purposes.
In this study, 2-3 modified enhancers (2R5S) in tandem are fused with a 87-bp (À80 to +7) proximal MCK promoter region to increase the level of musclespecific transcription. The modified promoters showed the increase in gene expression and retained high muscle-specificity in differentiated C2C12 myotubes as well as in mouse skeletal muscles. The specificity is consistent with previous study involving MCK promoters. 9, 15, 25, 36 Both the dMCK and tMCK promoters showed higher levels of activities than the CK6 promoter in differentiated C2C12 cells. The tMCK promoter was also stronger than the CMV promoter, in vitro and in vivo. The enhanced activities were apparently resulted from the multimerized MEF1 sites and right E-boxes in the basal MCK promoter 25, 26, 37 In addition to expression levels and tissue specificity, it has been reported that a series of small, truncated MCK regulatory cassettes containing the enhancer (E-box) and a proximal regulatory region of the MCK promoter were found to have varying levels of transgene expression among different striated muscles. 8, 9, 13, 24, 25 These studies led us to consider our promoters activities in different muscle tissues and heart. The dMCK-LacZ transgenic mice were generated to analyze the promoter activities in different tissues. In simple terms, strong LacZ expression was observed in skeletal muscles throughout the body, but the expression was very weak in the diaphragm and absent in the heart and other tissues such as the liver, kidneys and brain. To further explore gene expression in mdx mice, transgenic mice expressing a human minidystrophin gene driven by the dMCK promoter were created. Efficient minidystrophin expression was observed in a majority of the skeletal muscle tissues but again was minimal in the diaphragm and absent in the heart. The gene expression pattern is similar to an 1.35-kb MCK promoter in transgenic mdx mice. 13 As the cardiac transcriptional factor Nkx-2.5 does not bind to the E-box, 38, 39 it explains why the multimerized E-boxes, especially the modified 2RS5 E-boxes, increased gene expression in the skeletal muscles, but not in the heart. In addition, the fast-twitch myofiber preference by the dMCK and tMCK promoters are also consistent with earlier versions of the MCK promoter. 8, 9, 13 A recent report by Hauschka's group, however, has described a number of improved MCK-based promoters such as the MHCK7 that are not only active in the heart and diaphragm muscles, but also show reduced myofibertype preference. 26, 27 Our own effort here also identified a hybrid muscle-specific synthetic promoter, in which a modified MCK enhancer was fused with an original synthetic muscle promoter (C5-12) . 33 This 520 bp hybrid promoter (E-Syn) is 2-3 stronger than the original C5-12 promoter. The E-syn is active not only in the heart and diaphragm but also in other skeletal muscles without apparent myofiber-type preference, suitable for gene therapy intended for both muscle and heart. On the other hand, the dMCK and tMCK promoters are inactive in the heart, and they may be more suitable for gene expression intended only for skeletal muscles such as in muscle injury and atrophy. For example, muscle-restricted expression of insulin-like growth factor is beneficial for muscle-wasting diseases, but cardiac expression may be unfavorable.
9,40

Materials and methods
Construction of AAV vectors
A 595-bp section of the MCK enhancer/promoter region of the plasmid p(+enh206) 358MCKCAT 9 was cloned into the pBluescriptII KS (+) vector (Stratagene, La Jolla, CA, USA). The modified enhancer (2RS5) was generated according to previously described methods. 25 In addition to muscle-specific cis-elements, MEF-2, right E-box (MEF1) and A/T-rich elements were maintained in the enhancer region for the tissue-specificity in differentiated muscle. Another right E-box (5 0 -AACACCTGCTGC) and an S5 modified region (5 0 -GAGCGGTTA) were designed in the 2R5S enhancer to increase the MyoD-binding sites and enhancer activity. This modified enhancer was then ligated to the truncated 358MCK promoter to generate the CK6 promoter, which served as a control in this study. 25 Next, a double or triple tandem of 2RS5 enhancer sequences was ligated to the highly truncated regulation region down to base pairs À80 to +7, generating the dMCK or the tMCK promoter. The dMCK promoter contained two 2R5S enhancer sequences, resulting in a total of four right E-boxes and two S5 sequences (4R-2S5), whereas the tMCK promoter contained three 2R5S enhancer sequences, resulting in a total of six right E-boxes and 3S5 sequences (6R-3S5). The complete length of the promoters ranged from 509 to 720 bp. A small poly(A) signal sequence (60 bp) was placed next to the MCK promoters in pBluescriptII KS (+) vectors, 15 and in between them, a unique XhoI site was used to insert the luciferase gene. Bgl II restriction enzyme was used to cut the cassette of the modified MCK promoters and small polyA from pBluescriptII KS (+) vectors, and both of them were inserted into the AAV vector. The luciferase gene (Promega Biosciences Inc., San Luis Obispo, CA, USA) was inserted into the Xhol site of the AAV vectors containing the different modified MCK promoters (dMCK, tMCK, enh358MCK and CK6), and the new constructs were named AAV-dMCK-Luc, AAVtMCK-Luc, AAV-enh358MCK-Luc and AAV-CK6-Luc; AAV-enh358MCK-Luc and AAV-CK6-Luc were used as comparison vectors 9, 25 in addition to AAV-CMV-Luc. The muscle-specific synthetic promoter C5-12 (Syn, 312-bp) 33 was used to drive human dystrophin genes as we described in previous studies. 15 In addition, a hybrid muscle-specific synthetic promoter (E-syn) was generated by ligation of a 2RS5 enhancer to C5-12 promoter, and it was named E-Syn promoter.
The AAV recombinant viruses (AAV1, AAV2, AAV6 and AAV9) were made according to a previously published protocol. 41, 42 The final AAV viral genome numbers (v.g.) were measured by DNA dot blot 41 and were in the range of 5 Â 10 12 to 2 Â 10 13 v.g. ml
À1
. Twenty-four hours post-transfection, the 293 cells were harvested to determine the activity of luciferase as described previously. 43 All in vitro transfection experiments in C2C12 and 293 cells were performed in triplicate.
Mice and AAV vectors administration
The animals were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and approved by the University of Pittsburgh Animal Care and Use Committee. The 2-month-old male C57/BL10 mice were used to determine the activities of different promoters. Four mice in each group were treated with 2.5 Â 10 11 v.g. of AAV2-Luciferase viruses in 25 ml volume containing different modified MCK promoters via i.m. injection in the hind leg tibialis anterior (TA). The mice were killed 1 month post-treatment and TA muscle tissues were collected and measured for luciferase activity. Moreover, three male C57/BL10 mice in each group were used to test the promoter specificity and treated with 2.5 Â 10 12 v.g. of AAV2-luciferase vectors in a volume of 250 ml, injected into the mice via intrasplenic infusion by a small incision in the left hypochondriac region after the mice were anesthetized intraperitoneally with 2.5% of Avertin (100 ml per 10 g weight). The mice were killed 15 days post-treatment, and liver tissues were collected and measured for luciferase activity.
To compare the activity of the promoter C5-12 (Syn) in AAV6 and AAV9 in the heart, eight 3-month-old male mdx mice were divided into two groups to receive either 750 ml of AAV6-Syn-dys D 4173 (5 Â 10 11 v.g) or 750 ml of AAV9-Syn-dys D 4173 (5 Â 10 11 v.g) through tail vein injection. The dystrophin expression was evaluated by IF staining 2 months post-treatment.
Ten 3-month-old male mdx mice were divided into two groups for investigation of myofiber type preference of the Syn promoter in skeletal muscles. One group was treated by 30 ml of AAV1-Syn-Dys D 3990 (5 Â 10 9 v.g) by local injection to the TA muscle of both sides, and another group received 30 ml of AAV1-enh358MCK-Dys D 3990 (5 Â 10 9 v.g) as a control. The mice in both groups were killed 1 month after AAV vector treatment.
Another ten 3-month-old male mdx mice were divided into two groups for determining the enhancement of MCK enhancer in a hybrid muscle-specific synthetic promoter (E-Syn). Five were i.m. injected by 30 ml of AAV1-E-Syn-Dys D 3990 (5 Â 10 9 v.g) into TA muscles, and another five received 30 ml of AAV1-Syn-Dys D 3990 (5 Â 10 9 v.g); the mice were killed and TA muscles were selected for IF staining and western blot 3 months after treatment.
Luciferase assays
C2C12 and 293 cells were harvested in 200 ml of luciferase lysis buffer (0.05%. Triton X-100, 0.1 M TrisHCl, pH 7.8, 2 mM ethylenediaminetetraacetic acid), whereas TA muscles and liver tissues were dissolved in 1 ml of luciferase buffer according to the standard protocol of Promega Luciferase Assay System Kit (Promega Biosciences Inc., San Luis Obispo, CA, USA). After spinning at 13 000 r.p.m., 5 ml of supernatant from the cells and 30 ml of supernatant from the tissues were measured for protein concentration by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA), or used for luciferase activity test by Promega Luciferase Assay System and Luminometer LB953 AUTOLUMAT (Berthold, Wilbad, Germany). All the above-mentioned processes were controlled on ice.
LacZ transgenic mice and X-gal staining
The AAV-dMCK-LacZ plasmid was linearized by an XmnI single cut in the backbone of the AAV plasmid, then microinjected into the pronuclei of C57/6 and SJL zygotes according to published standard procedures. 44 The linearized AAV-dMCK-LacZ plasmid contained the ITR regions, dMCK promoter, LacZ gene and an SV40 polyA sequence. The LacZ gene was obtained from the plasmid pCMVb LacZ (Clontech, Mountain View, CA, USA) by XhoI/SalI double digestion. To identify transgenic mice positive for the LacZ gene, genomic DNA was extracted from mice tails and evaluated by PCR method. The pups of PCR-positive founders were killed at day 10 and assayed for X-gal staining, according to the published protocol. 45 Moreover, to identify whether the new MCK promoters were a benefit to mdx mice, PCRpositive founders were bred to 3-month-old C57/BL10 or mdx mice. Offspring that expressed the LacZ gene were identified by screening for b-galactosidase activity, and these mice were killed at day 20 and assayed for X-gal staining.
Creation of human minidystrophin transgenic mdx mice
The pAAV-dMCK-minidystrophin (Dys D 3849) plasmid was linearized by an AatII single cut in the backbone of the AAV plasmid, then microinjected into the pronuclei of C57/6 and SJL zygotes according to published standard procedures. 44 The linearized AAV plasmid contained the ITR regions, dMCK promoter, human minidystrophin gene including five rods (R1, R2, R22, R23, R24) with two hinges (1 and 4) and a small polyA sequence. 15 To identify transgenic mice positive for the human minidystrophin gene, genomic DNA was extracted from mice tails according to the protocol in Jackson Laboratory and evaluated by PCR using two primers set 5 0 -CCTAAAACGCCAAGTACAAC and 5 0 -AACTGGCTTCCAAATGGGAC that corresponded to 1550 and 3400 bp of minidystrophin gene. The minidystrophin-positive founders were identified by the presence of a 550-bp PCR product. The human minidystrophin transgenic male mice were mated with homozygous mdx female mice that were purchased from Jackson laboratory. After five generations, transgenic mice possessing the human minidystrophin gene with a homozygous mdx background were identified by PCR. The identified transgenic mice were killed at the age of 6
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Immunostaining of dystrophin and skeletal myosin
The muscle sections of 6-month-old C57/BL10, mdx and dMCK-Dys D 3849 transgenic mdx mice were used for IF analysis as described previously. 15 IF staining of dystrophin was performed with a primary polyclonal antibody (Rabbit serum anti-human dystrophin R22 and R23 regions, 1:500); whereas two different secondary antibodies presented red color and green color, respectively. The former (Cy 3 conjugated AffiniPure Goat anti-Rabbit IgG, 1:500) was purchased from Jackson ImmunoResearch (West Grove, PA, USA) and the latter (Alexa Fluor 488 chicken anti-rabbit IgG, 1:500) was purchased from Molecular Probes (Eugene, OR, USA). The staining of the myosin was performed using the VECTOR MOM Immunodetection Kit (Vector Laboratories, Burlingame, CA, USA). The monoclonal primary antibodies that were used for the IF staining of the fast myosin (skeletal-fast, 1:500) and slow myosin (skeletal-slow, 1:500) were purchased from Sigma (St Louis, MO, USA). The secondary antibody used in the myosin staining was Cy 3-conjugated AffiniPure Goat anti-mouse IgG (1:500), which was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
Statistical analysis
The significance of the difference between groups of experiments in vitro and in vivo was evaluated by analysis of variance followed by a two-tailed Student's t-test. Results were expressed at the mean+s.e.m. A P-value o0.05 was considered as the cut-off for significance.
